<p>Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - 免费报告) - Cantor Fitzgerald 的研究分析师在 8 月 12 日星期一发布的研究报告中提高了对 Lineage Cell Therapeutics 股票 2024 财年盈利的预期。Cantor Fitzgerald 分析师 K. Kluska 现预计该公司全年每股盈利为（$0.18），高于他们先前的预期（$0.20）。对于 Lineage Cell Therapeutics 当前全年盈利的共识预期为每股（$0.12）。</p>
<p>另外，HC Wainwright 在 5 月 6 日星期一的研究报告中重申了对 Lineage Cell Therapeutics 股票的&#34;买入&#34;评级，并设定了$7.00 的目标价。</p>
<p><strong>查看我们关于 Lineage Cell Therapeutics 的最新报告</strong></p>
<h2>Lineage Cell Therapeutics 股价下跌 1.3%</h2>
<p>Lineage Cell Therapeutics 股票周三开盘价为$0.83。Lineage Cell Therapeutics 的 52 周最低价为$0.82，52 周最高价为$1.61。该股市值为 1.5659 亿美元，市盈率为-5.92，β值为 1.29。</p>
<p>Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - 获取免费报告) 于 8 月 8 日星期四发布了其财报。公司本季度每股盈利（EPS）为（$0.03），超过了每股（$0.04）的共识预期。本季度公司营收为 141 万美元，超过了分析师预期的 128 万美元。Lineage Cell Therapeutics 的净利润率为-295.59%，净资产收益率为-34.92%。</p>
<h2>Lineage Cell Therapeutics 的机构交易</h2>
<p>一些机构投资者和对冲基金最近调整了他们对该公司的持股。XTX Topco Ltd 在第二季度购入了 Lineage Cell Therapeutics 的新股份，价值 6.1 万美元。Renaissance Technologies LLC 在第二季度增加了对 Lineage Cell Therapeutics 的持股，持股量增长了 10.0%，现在拥有公司股票的 583,622 股，价值 58.2 万美元。Rhumbline Advisers 在第二季度增加了对 Lineage Cell Therapeutics 的持股，持股量增长了 15.1%，现在拥有公司股票的 132,491 股，价值 13.2 万美元。纽约梅隆银行在第二季度增加了对 Lineage Cell Therapeutics 的持股，持股量增长了 35.7%，现在拥有公司股票的 435,958 股，价值 43.5 万美元。最后，Comerica 银行在第一季度将其对 Lineage Cell Therapeutics 的持股增加了 84,745.8%，现在拥有公司股票的 250,295 股，价值 37 万美元。目前 62.47% 的股份由机构投资者持有。</p>
<h2>Lineage Cell Therapeutics 公司简介（获取免费报告）</h2>
<p>Lineage Cell Therapeutics, Inc 是一家临床阶段的生物技术公司，致力于为美国和国际市场未满足的医疗需求开发新型细胞疗法。该公司开发了 OpRegen，一种同种异体视网膜色素上皮细胞替代疗法，目前正在进行干性年龄相关性黄斑变性治疗的 2a 期临床试验；OPC1，一种同种异体寡突触前体细胞疗法，目前正在进行多中心 1/2a 期临床试验，用于治疗颈椎脊髓损伤；以及 VAC，一种同种异体抗原呈递树突状细胞癌症免疫疗法，目前正在进行 I 期临床试验，用于治疗非小细胞肺癌。</p>
<h2>参见</h2>
<ul>
<li>我们喜欢的五只股票，比 Lineage Cell Therapeutics 更好</li>
<li>如何投资最佳加拿大股票</li>
<li>Instacart 股票以利润和人工智能推动增长</li>
<li>基础材料股票投资</li>
<li>PROCEPT BioRobotics 是否是外科机器人领域的下一个大事件？</li>
<li>股票情绪分析：它是如何工作的</li>
<li>波动市场中稳定性的前三只股息支付股票</li>
</ul>
<p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成，旨在为读者提供最快速和准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 这一只股票就是你需要的...（来自市场幕后）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ5"/></p>
<h2>您现在是否应该投资$1,000 购买 Lineage Cell Therapeutics 股票？</h2>
<p>在考虑购买 Lineage Cell Therapeutics 股票之前，您可能需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已确定了顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的五只股票...而 Lineage Cell Therapeutics 不在名单上。</p>
<p>尽管 Lineage Cell Therapeutics 目前在分析师中有&#34;买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

LCTX

<p>Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - 免费报告) - Cantor Fitzgerald 的研究分析师在 8 月 12 日星期一发布的研究报告中提高了他们对 Lineage Cell Therapeutics 股票 2024 财年盈利的预估。 Cantor Fitzgerald 分析师 K</p>

<p>Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2024 earnings estimates for shares of Lineage Cell Therapeutics in a research report issued on Monday, August 12th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($0.18) per share for the year, up from their previous estimate of ($0.20). The consensus estimate for Lineage Cell Therapeutics' current full-year earnings is ($0.12) per share.</p>
<div class="lb-trans"><p>Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - 免费报告) - Cantor Fitzgerald 的研究分析师在 8 月 12 日星期一发布的研究报告中提高了对 Lineage Cell Therapeutics 股票 2024 财年盈利的预期。Cantor Fitzgerald 分析师 K. Kluska 现预计该公司全年每股盈利为（$0.18），高于他们先前的预期（$0.20）。对于 Lineage Cell Therapeutics 当前全年盈利的共识预期为每股（$0.12）。</p>
</div><p>Separately, HC Wainwright restated a &#34;buy&#34; rating and set a $7.00 target price on shares of Lineage Cell Therapeutics in a research report on Monday, May 6th.</p>
<div class="lb-trans"><p>另外，HC Wainwright 在 5 月 6 日星期一的研究报告中重申了对 Lineage Cell Therapeutics 股票的&#34;买入&#34;评级，并设定了$7.00 的目标价。</p>
</div><p><strong>View Our Latest Report on Lineage Cell Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Lineage Cell Therapeutics 的最新报告</strong></p>
</div><h2>Lineage Cell Therapeutics Stock Down 1.3 %</h2>
<div class="lb-trans"><h2>Lineage Cell Therapeutics 股价下跌 1.3%</h2>
</div><p>Lineage Cell Therapeutics stock opened at $0.83 on Wednesday. Lineage Cell Therapeutics has a 52-week low of $0.82 and a 52-week high of $1.61. The stock has a market cap of $156.59 million, a price-to-earnings ratio of -5.92 and a beta of 1.29.</p>
<div class="lb-trans"><p>Lineage Cell Therapeutics 股票周三开盘价为$0.83。Lineage Cell Therapeutics 的 52 周最低价为$0.82，52 周最高价为$1.61。该股市值为 1.5659 亿美元，市盈率为-5.92，β值为 1.29。</p>
</div><p>Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.01. The company had revenue of $1.41 million for the quarter, compared to analysts' expectations of $1.28 million. Lineage Cell Therapeutics had a negative net margin of 295.59% and a negative return on equity of 34.92%.</p>
<div class="lb-trans"><p>Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - 获取免费报告) 于 8 月 8 日星期四发布了其财报。公司本季度每股盈利（EPS）为（$0.03），超过了每股（$0.04）的共识预期。本季度公司营收为 141 万美元，超过了分析师预期的 128 万美元。Lineage Cell Therapeutics 的净利润率为-295.59%，净资产收益率为-34.92%。</p>
</div><h2>Institutional Trading of Lineage Cell Therapeutics</h2>
<div class="lb-trans"><h2>Lineage Cell Therapeutics 的机构交易</h2>
</div><p>Several institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd purchased a new stake in Lineage Cell Therapeutics in the 2nd quarter worth $61,000. Renaissance Technologies LLC grew its position in shares of Lineage Cell Therapeutics by 10.0% during the second quarter. Renaissance Technologies LLC now owns 583,622 shares of the company's stock worth $582,000 after purchasing an additional 53,022 shares in the last quarter. Rhumbline Advisers raised its stake in Lineage Cell Therapeutics by 15.1% during the 2nd quarter. Rhumbline Advisers now owns 132,491 shares of the company's stock valued at $132,000 after purchasing an additional 17,411 shares during the period. Bank of New York Mellon Corp lifted its holdings in Lineage Cell Therapeutics by 35.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company's stock worth $435,000 after purchasing an additional 114,762 shares in the last quarter. Finally, Comerica Bank boosted its stake in Lineage Cell Therapeutics by 84,745.8% in the 1st quarter. Comerica Bank now owns 250,295 shares of the company's stock worth $370,000 after purchasing an additional 250,000 shares during the period. 62.47% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近调整了他们对该公司的持股。XTX Topco Ltd 在第二季度购入了 Lineage Cell Therapeutics 的新股份，价值 6.1 万美元。Renaissance Technologies LLC 在第二季度增加了对 Lineage Cell Therapeutics 的持股，持股量增长了 10.0%，现在拥有公司股票的 583,622 股，价值 58.2 万美元。Rhumbline Advisers 在第二季度增加了对 Lineage Cell Therapeutics 的持股，持股量增长了 15.1%，现在拥有公司股票的 132,491 股，价值 13.2 万美元。纽约梅隆银行在第二季度增加了对 Lineage Cell Therapeutics 的持股，持股量增长了 35.7%，现在拥有公司股票的 435,958 股，价值 43.5 万美元。最后，Comerica 银行在第一季度将其对 Lineage Cell Therapeutics 的持股增加了 84,745.8%，现在拥有公司股票的 250,295 股，价值 37 万美元。目前 62.47% 的股份由机构投资者持有。</p>
</div><h2>Lineage Cell Therapeutics Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Lineage Cell Therapeutics 公司简介（获取免费报告）</h2>
</div><p>Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.</p>
<div class="lb-trans"><p>Lineage Cell Therapeutics, Inc 是一家临床阶段的生物技术公司，致力于为美国和国际市场未满足的医疗需求开发新型细胞疗法。该公司开发了 OpRegen，一种同种异体视网膜色素上皮细胞替代疗法，目前正在进行干性年龄相关性黄斑变性治疗的 2a 期临床试验；OPC1，一种同种异体寡突触前体细胞疗法，目前正在进行多中心 1/2a 期临床试验，用于治疗颈椎脊髓损伤；以及 VAC，一种同种异体抗原呈递树突状细胞癌症免疫疗法，目前正在进行 I 期临床试验，用于治疗非小细胞肺癌。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than Lineage Cell Therapeutics</li>
<li>How to Invest in the Best Canadian Stocks</li>
<li>Instacart Stock Gains Momentum with Profits and AI-Powered Carts</li>
<li>Basic Materials Stocks Investing</li>
<li>Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>Top 3 Dividend-Paying Stocks for Stability in Volatile Markets</li>
</ul>
<div class="lb-trans"><h2>参见</h2>
<ul>
<li>我们喜欢的五只股票，比 Lineage Cell Therapeutics 更好</li>
<li>如何投资最佳加拿大股票</li>
<li>Instacart 股票以利润和人工智能推动增长</li>
<li>基础材料股票投资</li>
<li>PROCEPT BioRobotics 是否是外科机器人领域的下一个大事件？</li>
<li>股票情绪分析：它是如何工作的</li>
<li>波动市场中稳定性的前三只股息支付股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成，旨在为读者提供最快速和准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ This One stock is all you need... (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 这一只股票就是你需要的...（来自市场幕后）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9149&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Lineage Cell Therapeutics right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资$1,000 购买 Lineage Cell Therapeutics 股票？</h2>
</div><p>Before you consider Lineage Cell Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买 Lineage Cell Therapeutics 股票之前，您可能需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lineage Cell Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已确定了顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的五只股票...而 Lineage Cell Therapeutics 不在名单上。</p>
</div><p>While Lineage Cell Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Lineage Cell Therapeutics 目前在分析师中有&#34;买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

分析师对 Lineage Cell Therapeutics, Inc.（NYSEAMERICAN:LCTX）2024 财年收益的预期